Inhibitors of STEP as a Novel Treatment of Fragile X Syndrome

Inhibitors of STEP as a Novel Treatment of Fragile X Syndrome

With a $349,000 grant from FRAXA Research Foundation from 2008-2015, Dr. Paul Lombroso and his team at Yale University researched if inhibiting STEP could reduce behavioral abnormalities in fragile X syndrome. Results published.

Read more

Social Behavior as an Outcome Measure for Fragile X Clinical Trials

Social Behavior as an Outcome Measure for Fragile X Clinical Trials

One of the features of the fragile X mouse model which is relevant to the human fragile X syndrome (and autism) is social behavior. Several tests show consistent social behavioral abnormalities in the fragile X mouse model. With a $140,000 grant from FRAXA Research Foundation in 2012-2013, Dr. Willemsen at Erasmus University used social behavior tests to measure the effectiveness of several drug strategies.

Read more

AMPAkines and BDNF in Fragile X: UCI Researchers Restore Memory Process in Fragile X

AMPAkines and BDNF in Fragile X: UCI Researchers Restore Memory Process in Fragile X

With a $104,498 grant from FRAXA Research Foundation from 2003-2008, Dr. Julie Lauterborn at the University of California has done several studies on dentritic spines and finding treatment targets for memory retention in fragile X mice.

Read more

Studies of the Fragile X Knock-Out Mouse: Improving Memory Reversal Testing and Treatment with AMPAkines

Studies of the Fragile X Knock-Out Mouse: Improving Memory Reversal Testing and Treatment with AMPAkines

W. Ted Brown, MD, PhD — IBR, NY FRAXA Awards: $37,000 in 1998 $25,000 in 1997   To develop an improved test to show learning deficits in the FMR1 knock-out mouse model of fragile X, and then to test the effects of experimental drugs (Ampakines) that may be effective in treating these deficits.

Read more